These results are in contrast to recently reported results by Preto and coworkers [55], who reported that sorafenib treatment only significantly induced apoptosis in anaplastic thyroid cells harboring a homozygous BRAFV600E mutation (8505C cell line), but not in thyroid carcinoma cells with wildtype BRAF (C643 and TPC1 cell lines). The gene discussed is BRAF; the disease is thyroid gland carcinoma.